Physician profile
Lena M Tim
NPI 1407573736
$3,869.48
in general payments reported to CMS, 2019-2025
31 companies · $762 in 2025
The $762 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,354 · 2024: $1,753 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.13 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $423.63 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $372.54 | 2023-2025 | |
| Abbvie INC. | $361.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $358.06 | 2023-2025 | Breztri, Airsupra, Fasenra |
| Amgen INC. | $326.31 | 2023-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $272.30 | 2023-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $257.89 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $148.90 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $143.68 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $129.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $126.38 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $98.60 | 2024-2025 | Gemtesa |
| Inogen, INC. | $94.93 | 2023-2025 | Inogen |
| Merck Sharp & Dohme LLC | $90.50 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $86.62 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $79.37 | 2024 | Auvelity, Sunosi |
| Exact Sciences Corporation | $48.15 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.38 | 2023-2024 | Caplyta |
| Ironwood Pharmaceuticals, INC | $41.93 | 2023 | Linzess |
| Kowa Pharmaceuticals America, INC. | $39.38 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Millicent US INC | $32.52 | 2024 | Femring, Intrarosa |
| Seqirus USA INC | $26.49 | 2025 | Flucelvax, Fluad |
| Horizon Therapeutics Plc | $24.61 | 2023 | Krystexxa |
| Medtronic, INC. | $23.07 | 2023 | Intellis Adaptivestim |
| Dexcom, INC. | $22.69 | 2024 | Dexcom G6 Transmitter |
| Teleflex LLC | $21.64 | 2025 | Urolift |
| Exeltis, USA INC. | $18.34 | 2024 | Slynd |
| Ibsa Pharma INC. | $16.42 | 2024 | Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $14.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Tim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.